Jahresforschungsprogramm 2023
- #161 Update: Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
- #160: Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis
- #159: Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)
- #158: Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC)
- #157: Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM)
- #156: Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
- #155: Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
- #154: Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC)
- #153: Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC)
- #152: Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM)
- #151: Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL)
- #150/Update: Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)
- #149: Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM)
- #148: Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)
- #147: Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation
- #146/Update: Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma
- #145/Update: Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
- #144 Update: Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease
- #143/Update: Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)
- #142/2. Update: Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- #141/Update: Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)
- #140/Update: Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer
- #139/Update: Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)
- #138/2. Update: Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)
- #137/Update: Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer
- #136/ Update: Trifluridine / tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)
- #135 Update: Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)
- #134/Update: Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer
- #133/Update: Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC)
- #132/Update: Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma
- #131: Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)
- #130/2. Update: Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
- #129/Update: Lisocabtagene maraleucel (Breyanzi®) bei DLBCL, HGBCL, PMBCL, FL3B
- #128/Update: Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
- #127/2. Update: Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma
- #126/Update: Ivosidenib (Tibsovo®, Tidhesco®) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML)
- #125/2. Update: Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
- #124: Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency)
- #123/Update: Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
- #122/2. Update: Oportuzumab monatox (Vicineum®) for Bladder cancer
- #121/2. Update: Nadofaragen Firadenovec (Adstiladrin®) for Bladder cancer
- #120/Update: Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer
- #119/Update: Tremelimumab (Tremelimumab AstraZeneca®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC
- #118/2. Update: Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) for HCC
- #117/Update: Olaparib (Lynparza®) for mCRPC
